These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

239 related articles for article (PubMed ID: 33078904)

  • 1. Efficacy and safety of combination PD-1/PD-L1 checkpoint inhibitors for malignant solid tumours: A systematic review.
    Yao Q; Gu L; Su R; Chen B; Cao H
    J Cell Mol Med; 2020 Nov; 24(22):13494-13506. PubMed ID: 33078904
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Efficacy and safety of PD-L1 inhibitors versus PD-1 inhibitors in first-line treatment with chemotherapy for extensive-stage small-cell lung cancer.
    Yu H; Chen P; Cai X; Chen C; Zhang X; He L; Zhou Y; Hong S; Zhang B
    Cancer Immunol Immunother; 2022 Mar; 71(3):637-644. PubMed ID: 34297160
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Differences in oncological and toxicity outcomes between programmed cell death-1 and programmed cell death ligand-1 inhibitors in metastatic renal cell carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Quhal F; Katayama S; Mostafaei H; Laukhtina E; Schuettfort VM; D'Andrea D; Egawa S; Bensalah K; Schmidinger M; Powles T; Shariat SF
    Cancer Treat Rev; 2021 Sep; 99():102242. PubMed ID: 34153830
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Immune-checkpoint inhibitor plus chemotherapy versus conventional chemotherapy for first-line treatment in advanced non-small cell lung carcinoma: a systematic review and meta-analysis.
    Zhou Y; Chen C; Zhang X; Fu S; Xue C; Ma Y; Fang W; Yang Y; Hou X; Huang Y; Zhao H; Hong S; Zhang L
    J Immunother Cancer; 2018 Dec; 6(1):155. PubMed ID: 30577837
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evaluation of the effectiveness and safety of combining PD-1/PD-L1 inhibitors with anti-angiogenic agents in unresectable hepatocellular carcinoma: a systematic review and meta-analysis.
    Zhu H; Zhao W; Chen H; Zhu X; You J; Jin C
    Front Immunol; 2024; 15():1468440. PubMed ID: 39355241
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Use of Immunotherapy With Programmed Cell Death 1 vs Programmed Cell Death Ligand 1 Inhibitors in Patients With Cancer: A Systematic Review and Meta-analysis.
    Duan J; Cui L; Zhao X; Bai H; Cai S; Wang G; Zhao Z; Zhao J; Chen S; Song J; Qi C; Wang Q; Huang M; Zhang Y; Huang D; Bai Y; Sun F; Lee JJ; Wang Z; Wang J
    JAMA Oncol; 2020 Mar; 6(3):375-384. PubMed ID: 31876895
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Safety and Efficacy of PD-1/PD-L1 inhibitors combined with radiotherapy in patients with non-small-cell lung cancer: a systematic review and meta-analysis.
    Geng Y; Zhang Q; Feng S; Li C; Wang L; Zhao X; Yang Z; Li Z; Luo H; Liu R; Lu B; Wang X
    Cancer Med; 2021 Feb; 10(4):1222-1239. PubMed ID: 33465302
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The Efficacy and Safety of PD-1/PD-L1 Inhibitors in Combination with Conventional Therapies for Advanced Solid Tumors: A Meta-Analysis.
    Nie RC; Zhao CB; Xia XW; Luo YS; Wu T; Zhou ZW; Yuan SQ; Wang Y; Li YF
    Biomed Res Int; 2020; 2020():5059079. PubMed ID: 32461994
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparative efficacy and safety of PD-1/PD-L1 Inhibitors versus platinum-based chemotherapy for the first-line treatment of advanced non-small cell lung cancer: a meta analysis of randomized controlled trials.
    Li ZQ; Yan HC; Gu JJ; Yang YL; Zhang MK; Fang XJ
    Pharmacol Res; 2020 Oct; 160():105194. PubMed ID: 32937178
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Association of PD-L1 expression status with the efficacy of PD-1/PD-L1 inhibitors and overall survival in solid tumours: A systematic review and meta-analysis.
    Liu X; Guo CY; Tou FF; Wen XM; Kuang YK; Zhu Q; Hu H
    Int J Cancer; 2020 Jul; 147(1):116-127. PubMed ID: 31633798
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Effectivity and safety of PD-1/PD-L1 inhibitors for different level of PD-L1-positive, advanced NSCLC: A meta-analysis of 4939 patients from randomized controlled trials.
    Shi Y; Duan J; Guan Q; Xue P; Zheng Y
    Int Immunopharmacol; 2020 Jul; 84():106452. PubMed ID: 32339922
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The benefits and risks of CTLA4 inhibitor plus PD1/PDL1 inhibitor in stage IIIB/IV non-small cell lung cancer: A systematic analysis and meta-analysis based on randomized controlled trials.
    Liu Q; Fang Z; Liu M; Xu R; Yi F; Wei Y; Zeng L; Zhang W
    J Clin Pharm Ther; 2021 Dec; 46(6):1519-1530. PubMed ID: 34101874
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and Safety of Programmed Death 1/Programmed Death-Ligand 1 Plus Cytotoxic T-Lymphocyte-Associated Antigen 4 Inhibitors for Advanced or Metastatic Non-Small Cell Lung Cancer: A Meta-analysis Based on Randomized Controlled Trials.
    Ren W; Fang Y; He Y; Ren Y; Wang M; Xu A; Ruan J; Tao Q
    Ther Drug Monit; 2024 Aug; 46(4):422-433. PubMed ID: 38840327
    [TBL] [Abstract][Full Text] [Related]  

  • 14. First-line immune-checkpoint inhibitor combination therapy for chemotherapy-eligible patients with metastatic urothelial carcinoma: A systematic review and meta-analysis.
    Mori K; Pradere B; Moschini M; Mostafaei H; Laukhtina E; Schuettfort VM; Sari Motlagh R; Soria F; Teoh JYC; Egawa S; Powles T; Shariat SF;
    Eur J Cancer; 2021 Jul; 151():35-48. PubMed ID: 33962359
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of Clinicopathological Characteristics on the Survival of Patients Treated with PD-1/PD-L1 Inhibitor Monotherapy or Combination Therapy for Advanced Cancer: A Systemic Review and Meta-Analysis.
    Wei Y; Li Y; Du Q; Peng X; Jin J; Guo H; Li Y; Li Q
    J Immunol Res; 2020; 2020():5269787. PubMed ID: 33381603
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Efficacy and safety of anti-PD-1/PD-L1-based dual immunotherapies versus PD-1/PD-L1 inhibitor alone in patients with advanced solid tumor: a systematic review and meta-analysis.
    Chen Y; Han H; Cheng J; Cheng Q; Zhu S; Zhan P; Liu H; Song Y; Lv T
    Cancer Immunol Immunother; 2024 Jun; 73(8):155. PubMed ID: 38834888
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Assessment of the safety and efficacy of combination chemotherapy and PD-1/PD-L1 inhibitor treatment of breast cancer: A meta-analysis.
    Qian D; Xu Y; Wu Y; Qiu J; Hong W; Meng X
    Chin Med J (Engl); 2023 Jul; 136(14):1663-1670. PubMed ID: 37279392
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Efficacy and safety of PD-1/PD-L1 inhibitors in triple-negative breast cancer: a systematic review and meta-analysis.
    Zhang M; Song J; Yang H; Jin F; Zheng A
    Acta Oncol; 2022 Sep; 61(9):1105-1115. PubMed ID: 35939538
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The efficacy and safety of PD-1/PD-L1 inhibitors versus chemotherapy in patients with previously treated advanced non-small-cell lung cancer: A meta-analysis.
    Wu LG; Zhou DN; Wang T; Ma JZ; Sui H; Deng WL
    Medicine (Baltimore); 2021 Mar; 100(12):e25145. PubMed ID: 33761681
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Efficacy of PD-1 & PD-L1 inhibitors in older adults: a meta-analysis.
    Elias R; Giobbie-Hurder A; McCleary NJ; Ott P; Hodi FS; Rahma O
    J Immunother Cancer; 2018 Apr; 6(1):26. PubMed ID: 29618381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.